We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Avg Time Held
21.7
quarters
Top 10 Avg Time Held
6.6
quarters
Top 20 Avg Time Held
9.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1926
Caesarstone
CSTE
$98.5M
| $3.01K | ﹤0.01% |
+1,530
| New | +$3.46K |
2025 Q2
0 quarters
|
|
1927
Tyra Biosciences
TYRA
$1.37B
| $3K | ﹤0.01% |
314
-161
| -34% | -$1.53K |
2023 Q1
9 quarters
|
|
1928
AB InBev
BUD
$152B
| $2.96K | ﹤0.01% |
43
| – | – |
2024 Q3
3 quarters
|
|
1929
Oil-Dri
ODC
$1.24B
| $2.89K | ﹤0.01% |
49
| – | – |
2025 Q1
1 quarter
|
|
1930
Cipher Digital
CIFR
$5.61B
| $2.86K | ﹤0.01% |
598
-121,380
| -100% | -$393K |
2024 Q4
2 quarters
|
|
1931
CS Disco
LAW
$287M
| $2.82K | ﹤0.01% |
+646
| New | +$2.53K |
2025 Q2
0 quarters
|
|
1932
Virgin Galactic
SPCE
$431M
| $2.81K | ﹤0.01% |
1,030
-1,955,169
| -100% | -$5.99M |
2024 Q3
3 quarters
|
|
1933
NatWest
NWG
$67.9B
| $2.77K | ﹤0.01% |
196
+45
| +30% | +$595 |
2024 Q4
2 quarters
|
|
1934
Douglas Dynamics
PLOW
$904M
| $2.77K | ﹤0.01% |
+94
| New | +$2.47K |
2025 Q2
0 quarters
|
|
1935
Acrivon Therapeutics
ACRV
$81.8M
| $2.76K | ﹤0.01% |
+2,318
| New | +$3.18K |
2025 Q2
0 quarters
|
|
1936
Franklin Financial Services
FRAF
$282M
| $2.73K | ﹤0.01% |
79
| – | – |
2025 Q1
1 quarter
|
|
1937
SITE Centers
SITC
$163M
| $2.73K | ﹤0.01% |
241
-90
| -27% | -$1.08K |
2022 Q1
13 quarters
|
|
1938
ALX Oncology
ALXO
$173M
| $2.71K | ﹤0.01% |
6,541
| – | – |
2024 Q4
2 quarters
|
|
1939
Riot Platforms
RIOT
$6.34B
| $2.71K | ﹤0.01% |
+240
| New | +$2.04K |
2025 Q2
0 quarters
|
|
1940
Goldgroup Mining
GORO
$576M
| $2.7K | ﹤0.01% |
1,105
| – | – |
2023 Q3
7 quarters
|
|
1941
Curbline Properties
CURB
$3.11B
| $2.69K | ﹤0.01% |
+118
| New | +$2.71K |
2025 Q2
0 quarters
|
|
1942
Recursion Pharmaceuticals
RXRX
$2.34B
| $2.69K | ﹤0.01% |
+531
| New | +$2.61K |
2025 Q2
0 quarters
|
|
1943
Owlet
OWLT
$138M
| $2.65K | ﹤0.01% |
+316
| New | +$1.58K |
2025 Q2
0 quarters
|
|
1944
Bicara Therapeutics
BCAX
$1.16B
| $2.65K | ﹤0.01% |
285
-11,715
| -98% | -$140K |
2024 Q3
3 quarters
|
|
1945
PrimeEnergy Resources
PNRG
$340M
| $2.49K | ﹤0.01% |
17
| – | – |
2024 Q4
2 quarters
|
|
1946
Radiant Logistics
RLGT
$432M
| $2.41K | ﹤0.01% |
396
+101
| +34% | +$604 |
2024 Q4
2 quarters
|
|
1947
Ouster
OUST
$2.88B
| $2.33K | ﹤0.01% |
+96
| New | +$1.17K |
2025 Q2
0 quarters
|
|
1948
Madison Square Garden
MSGE
$3.82B
| $2.28K | ﹤0.01% |
57
-12,300
| -100% | -$435K |
2024 Q1
5 quarters
|
|
1949
Tenaya Therapeutics
TNYA
$130M
| $2.27K | ﹤0.01% |
3,709
| – | – |
2025 Q1
1 quarter
|
|
1950
Ingles Markets
IMKTA
$1.63B
| $2.22K | ﹤0.01% |
35
-5
| -13% | -$311 |
2013 Q2
48 quarters
|
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.